Alnylam reports positive topline results from apollo-b phase 3 study of patisiran in patients with attr amyloidosis with cardiomyopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the apollo-b phase 3 study of patisiran, an investigational rnai therapeutic in development for the treatment of transthyretin-mediated (attr) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-minute walk test (6-mwt) at 12 months compared to placebo (p-value 0.0162). the study also met the first secondary endpoint
ALNY Ratings Summary
ALNY Quant Ranking